Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...
Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback